The targeted cancers were hormone-receptor-positive advanced breast cancer, advanced neuroendocrine tumors associated with carcinoid syndrome, advanced renal cell carcinoma, and advanced pancreatic neuroendocrine tumor. The gene discussed is NR4A1; the disease is breast carcinoma.